Canada - Toronto Stock Exchange - TSX:NUMI - CA67054W1032 - Common Stock
The current stock price of NUMI.CA is 0.05 CAD. In the past month the price increased by 25%. In the past year, price decreased by -58.33%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.59 | 3.15B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.45B | ||
| CRON.CA | CRONOS GROUP INC | 23.93 | 1.28B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.67 | 918.91M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.38 | 638.55M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | 122.4 | 610.04M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 527.67M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 21.69 | 357.01M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 334.13M | ||
| HITI.CA | HIGH TIDE INC | N/A | 322.75M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 283.44M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 293.64M |
Numinus Wellness, Inc. engages in the development of psychedelic-centered therapeutic products. The company is headquartered in Montreal, Quebec. The firm focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.
NUMINUS WELLNESS INC
393 Laurier Ave W
MONTREAL QUEBEC V6B 1R4 CA
CEO: Payton Nyquvest
Employees: 0
Phone: 18336864687.0
Numinus Wellness, Inc. engages in the development of psychedelic-centered therapeutic products. The company is headquartered in Montreal, Quebec. The firm focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.
The current stock price of NUMI.CA is 0.05 CAD. The price increased by 42.86% in the last trading session.
NUMI.CA does not pay a dividend.
NUMI.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NUMINUS WELLNESS INC (NUMI.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.11).
NUMINUS WELLNESS INC (NUMI.CA) currently has 0 employees.
NUMINUS WELLNESS INC (NUMI.CA) has a market capitalization of 16.12M CAD. This makes NUMI.CA a Nano Cap stock.
ChartMill assigns a technical rating of 4 / 10 to NUMI.CA. When comparing the yearly performance of all stocks, NUMI.CA turns out to be only a medium performer in the overall market: it outperformed 45.79% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to NUMI.CA. NUMI.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months NUMI.CA reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 37.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -213.24% | ||
| ROE | -644.74% | ||
| Debt/Equity | 0.95 |
For the next year, analysts expect an EPS growth of 58.33% and a revenue growth -18.04% for NUMI.CA